Literature DB >> 21203871

Telomeres and prognosis in patients with chronic lymphocytic leukaemia.

Ludger Sellmann1, Dirk de Beer, Marius Bartels, Bertram Opalka, Holger Nückel, Ulrich Dührsen, Jan Dürig, Marc Seifert, Dörte Siemer, Ralf Küppers, Gabriela M Baerlocher, Alexander Röth.   

Abstract

In the present study, telomere length, telomerase activity, the mutation load of immunoglobulin variable heavy chain (IGHV) genes, and established prognostic factors were investigated in 78 patients with chronic lymphocytic leukaemia (CLL) to determine the impact of telomere biology on the pathogenesis of CLL. Telomere length was measured by an automated multi-colour flow-FISH, and an age-independent delta telomere length (ΔTL) was calculated. CLL with unmutated IGHV genes was associated with shorter telomeres (p = 0.002). Furthermore, we observed a linear correlation between the frequency of IGHV gene mutations and elongation of telomeres (r = 0.509, p < 0.001). With respect to prognosis, a threshold ΔTL of -4.2 kb was the best predictor for progression-free and overall survival. ΔTL was not significantly altered over time or with therapy. The correlation between the mutational load in IGHV genes and the ΔTL in CLL might reflect the initial telomere length of the putative cell of origin (pre- versus post-germinal center B cells). In conclusion, the ΔTL is a reliable prognostic marker for patients with CLL. Short telomeres and high telomerase activity as occurs in some patients with CLL with a worse prognosis might be an ideal target for treatment with telomerase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21203871     DOI: 10.1007/s12185-010-0750-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  40 in total

Review 1.  Chronic lymphocytic leukemia.

Authors:  T J Kipps
Journal:  Curr Opin Hematol       Date:  2000-07       Impact factor: 3.284

Review 2.  Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT).

Authors:  J C Poole; L G Andrews; T O Tollefsbol
Journal:  Gene       Date:  2001-05-16       Impact factor: 3.688

3.  Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome.

Authors:  Hiroki Yamaguchi; Gabriela M Baerlocher; Peter M Lansdorp; Stephen J Chanock; Olga Nunez; Elaine Sloand; Neal S Young
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

Review 4.  Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis.

Authors:  H Döhner; S Stilgenbauer; K Döhner; M Bentz; P Lichter
Journal:  J Mol Med (Berl)       Date:  1999-02       Impact factor: 4.599

5.  Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status.

Authors:  Pawel Grabowski; Magnus Hultdin; Karin Karlsson; Gerard Tobin; Anna Aleskog; Ulf Thunberg; Anna Laurell; Christer Sundström; Richard Rosenquist; Göran Roos
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

6.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

Review 7.  The implication of telomerase activity and telomere stability for replicative aging and cellular immortality (Review).

Authors:  M Engelhardt; U M Martens
Journal:  Oncol Rep       Date:  1998 Sep-Oct       Impact factor: 3.906

8.  Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia.

Authors:  A Röth; J Dürig; H Himmelreich; S Bug; R Siebert; U Dührsen; P M Lansdorp; G M Baerlocher
Journal:  Leukemia       Date:  2007-09-27       Impact factor: 11.528

9.  Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia.

Authors:  O E Bechter; W Eisterer; G Pall; W Hilbe; T Kühr; J Thaler
Journal:  Cancer Res       Date:  1998-11-01       Impact factor: 12.701

10.  Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia.

Authors:  Göran Roos; Alexander Kröber; Pawel Grabowski; Dirk Kienle; Andreas Bühler; Hartmut Döhner; Richard Rosenquist; Stephan Stilgenbauer
Journal:  Blood       Date:  2007-11-28       Impact factor: 22.113

View more
  12 in total

1.  Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia.

Authors:  Patricia Dos Santos; Julieta Panero; Virginia Palau Nagore; Carmen Stanganelli; Raimundo F Bezares; Irma Slavutsky
Journal:  Tumour Biol       Date:  2015-05-26

2.  Multiple Pathways Control the Reactivation of Telomerase in HTLV-I-Associated Leukemia.

Authors:  Marcia Bellon; Christophe Nicot
Journal:  Int J Cancer Oncol       Date:  2015-06-02

3.  Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.

Authors:  Ludger Klewes; Rhea Vallente; Eric Dupas; Carolin Brand; Dietrich Grün; Amanda Guffei; Chirawadee Sathitruangsak; Julius A Awe; Alexandra Kuzyk; Daniel Lichtensztejn; Pille Tammur; Tiiu Ilus; Anu Tamm; Mari Punab; Morel Rubinger; Adebayo Olujohungbe; Sabine Mai
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

Review 4.  Association between telomere length and survival in cancer patients: a meta-analysis and review of literature.

Authors:  Xinsen Xu; Kai Qu; Qing Pang; Zhixin Wang; Yanyan Zhou; Chang Liu
Journal:  Front Med       Date:  2016-05-16       Impact factor: 4.592

Review 5.  Telomere Length and Hematological Disorders: A Review.

Authors:  Beatriz Maria Dias Nogueira; Caio Bezerra Machado; Raquel Carvalho Montenegro; Maria Elisabete Amaral DE Moraes; Caroline Aquino Moreira-Nunes
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 6.  The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation.

Authors:  Limengmeng Wang; Haowen Xiao; Xing Zhang; Chong Wang; He Huang
Journal:  J Hematol Oncol       Date:  2014-08-20       Impact factor: 17.388

7.  Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia.

Authors:  Juhi Ojha; Veryan Codd; Christopher P Nelson; Nilesh J Samani; Ivan V Smirnov; Nils R Madsen; Helen M Hansen; Adam J de Smith; Paige M Bracci; John K Wiencke; Margaret R Wrensch; Joseph L Wiemels; Kyle M Walsh
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-13       Impact factor: 4.254

8.  Telomere length in relation to immunological parameters in patients with renal cell carcinoma.

Authors:  Ulrika Svenson; Elisabeth Grönlund; Ingegerd Söderström; Raviprakash T Sitaram; Börje Ljungberg; Göran Roos
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

9.  Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.

Authors:  May Shawi; Tsz Wai Chu; Veronica Martinez-Marignac; Y Yu; Sergei M Gryaznov; James B Johnston; Susan P Lees-Miller; Sarit E Assouline; Chantal Autexier; Raquel Aloyz
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

10.  Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Authors:  J C Strefford; L Kadalayil; J Forster; M J J Rose-Zerilli; A Parker; T T Lin; N Heppel; K Norris; A Gardiner; Z Davies; D Gonzalez de Castro; M Else; A J Steele; H Parker; T Stankovic; C Pepper; C Fegan; D Baird; A Collins; D Catovsky; D G Oscier
Journal:  Leukemia       Date:  2015-08-10       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.